With no approved therapies for NRG-1 cancers, zenocutuzumab offers a promising treatment option for this patient population. Zenocutuzumab (MCLA-128) had anti-tumor properties in multiple advanced, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback